ADCT Profitability Analysis: Past Growth, Margins, Return on Capital, Free Cash Flow, and more - ADC Therapeutics SA - Alpha Spread

ADC Therapeutics SA
NYSE:ADCT

Watchlist Manager
ADC Therapeutics SA Logo
ADC Therapeutics SA
NYSE:ADCT
Watchlist
Price: 2.7 USD -4.59% Market Closed
Market Cap: 259.8m USD
Have any thoughts about
ADC Therapeutics SA?
Write Note

Profitability Summary

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Past Growth

To be successful and remain in business, both growth and profitability are important and necessary. Net Income growth is often seen as a sign of a company's efficiency from an operational standpoint, but is influenced heavily by a company's goals and challenges and should therefore be assessed in conjunction with other metrics like revenue and operating income growth.

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Earnings Waterfall
ADC Therapeutics SA

Revenue
119.5m USD
Cost of Revenue
-6.6m USD
Gross Profit
112.9m USD
Operating Expenses
-378.6m USD
Operating Income
-265.7m USD
Other Expenses
-105.3m USD
Net Income
-371m USD

Margins Comparison
ADC Therapeutics SA Competitors

Country Company Market Cap Gross
Margin
Operating
Margin
Net
Margin
CH
ADC Therapeutics SA
NYSE:ADCT
260.5m USD
94%
-222%
-310%
US
Abbvie Inc
NYSE:ABBV
341.5B USD
67%
29%
10%
US
Amgen Inc
NASDAQ:AMGN
172.2B USD
63%
20%
10%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
125.7B USD
87%
31%
32%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.8B USD
86%
41%
-5%
US
Epizyme Inc
F:EPE
94.1B EUR
76%
-370%
-392%
AU
CSL Ltd
ASX:CSL
146.9B AUD
52%
26%
18%
US
Gilead Sciences Inc
NASDAQ:GILD
98.1B USD
77%
37%
4%
US
Palatin Technologies Inc
LSE:0KF3
44.5B USD
97%
-555%
-557%
US
Seagen Inc
F:SGT
39.3B EUR
75%
-33%
-33%
NL
argenx SE
NASDAQ:ARGX
32.4B USD
89%
-22%
-14%
Country CH
Market Cap 260.5m USD
Gross Margin
94%
Operating Margin
-222%
Net Margin
-310%
Country US
Market Cap 341.5B USD
Gross Margin
67%
Operating Margin
29%
Net Margin
10%
Country US
Market Cap 172.2B USD
Gross Margin
63%
Operating Margin
20%
Net Margin
10%
Country US
Market Cap 125.7B USD
Gross Margin
87%
Operating Margin
31%
Net Margin
32%
Country US
Market Cap 120.8B USD
Gross Margin
86%
Operating Margin
41%
Net Margin
-5%
Country US
Market Cap 94.1B EUR
Gross Margin
76%
Operating Margin
-370%
Net Margin
-392%
Country AU
Market Cap 146.9B AUD
Gross Margin
52%
Operating Margin
26%
Net Margin
18%
Country US
Market Cap 98.1B USD
Gross Margin
77%
Operating Margin
37%
Net Margin
4%
Country US
Market Cap 44.5B USD
Gross Margin
97%
Operating Margin
-555%
Net Margin
-557%
Country US
Market Cap 39.3B EUR
Gross Margin
75%
Operating Margin
-33%
Net Margin
-33%
Country NL
Market Cap 32.4B USD
Gross Margin
89%
Operating Margin
-22%
Net Margin
-14%

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Return on Capital Comparison
ADC Therapeutics SA Competitors

Country Company Market Cap ROE ROA ROCE ROIC
CH
ADC Therapeutics SA
NYSE:ADCT
260.5m USD
529%
-84%
-72%
-285%
US
Abbvie Inc
NYSE:ABBV
341.5B USD
54%
4%
16%
12%
US
Amgen Inc
NASDAQ:AMGN
172.2B USD
49%
3%
9%
8%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
125.7B USD
17%
13%
14%
17%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.8B USD
-3%
-2%
25%
-84%
US
Epizyme Inc
F:EPE
94.1B EUR
-877%
-67%
-73%
-182%
AU
CSL Ltd
ASX:CSL
146.9B AUD
16%
7%
12%
9%
US
Gilead Sciences Inc
NASDAQ:GILD
98.1B USD
5%
2%
23%
13%
US
Palatin Technologies Inc
LSE:0KF3
44.5B USD
-588%
-178%
-395%
-5 705%
US
Seagen Inc
F:SGT
39.3B EUR
-28%
-21%
-27%
-39%
NL
argenx SE
NASDAQ:ARGX
32.4B USD
-8%
-7%
-12%
-31%
Country CH
Market Cap 260.5m USD
ROE
529%
ROA
-84%
ROCE
-72%
ROIC
-285%
Country US
Market Cap 341.5B USD
ROE
54%
ROA
4%
ROCE
16%
ROIC
12%
Country US
Market Cap 172.2B USD
ROE
49%
ROA
3%
ROCE
9%
ROIC
8%
Country US
Market Cap 125.7B USD
ROE
17%
ROA
13%
ROCE
14%
ROIC
17%
Country US
Market Cap 120.8B USD
ROE
-3%
ROA
-2%
ROCE
25%
ROIC
-84%
Country US
Market Cap 94.1B EUR
ROE
-877%
ROA
-67%
ROCE
-73%
ROIC
-182%
Country AU
Market Cap 146.9B AUD
ROE
16%
ROA
7%
ROCE
12%
ROIC
9%
Country US
Market Cap 98.1B USD
ROE
5%
ROA
2%
ROCE
23%
ROIC
13%
Country US
Market Cap 44.5B USD
ROE
-588%
ROA
-178%
ROCE
-395%
ROIC
-5 705%
Country US
Market Cap 39.3B EUR
ROE
-28%
ROA
-21%
ROCE
-27%
ROIC
-39%
Country NL
Market Cap 32.4B USD
ROE
-8%
ROA
-7%
ROCE
-12%
ROIC
-31%

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

See Also

Discover More
Back to Top